UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 26, 2005
Adams Respiratory Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | | | | |
| Delaware | | 000-51445 | | 75-2725552 |
(State or Other Jurisdiction of
Incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 425 Main Street, Chester, New Jersey | | 07930 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(908) 879-1400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On October 26, 2005, the Board of Directors (the “Board”) of Adams Respiratory Therapeutics, Inc. (the “Company”) elected John N. Lilly to fill the vacancy created by the retirement of John Q. Adams, Sr. from the Board on October 14, 2005. The Board also appointed Mr. Lilly as a member of the Compensation Committee. Mr. Lilly was appointed as a Class I Director, whose term will expire in fiscal year 2006.
There are no arrangements between Mr. Lilly and any other person pursuant to which Mr. Lilly was selected as a director, nor are there any transactions to which the Company or any subsidiary thereof is a party and in which Mr. Lilly has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
Item 8.01 Other Events.
On October 26, 2005, the Company issued a press release announcing the election of John N. Lilly to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference in its entirety.
Item 9.01
(c) Exhibits
| | | |
| EXHIBIT NO. | | DESCRIPTION |
| 99.1 | | Press Release dated October 26, 2005 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | ADAMS RESPIRATORY THERAPEUTICS, INC.
| |
| | By: | /s/ Walter E. Riehemann | |
| | | Walter E. Riehemann | |
| | | Executive Vice President, Chief Legal and Compliance Officer and Secretary | |
| |
Dated: October 27, 2005
